ChemCom is the leading discovery company for products and services related to chemical communications mediated by human olfactory and taste receptors. ChemCom offers a unique, patented technological platform based on an exclusive worldwide license acquired from Duke University. Its offices are located in Brussels on the Erasme Medical Campus (ULB) where it currently employs 13 people. The findings have been gathered in a database that enables the Company to reproduce an artificial nose that expresses the whole repertoire of human Olfactory Receptors (hORs). The applications of ChemCom’s research allow for the development of new products and technologies for consumer needs in the area of flavors & fragrances, but also all industries that deal with odor or taste issues. The applications of ChemCom’s research leads the development of new products and technologies for consumer needs in multiple areas.
In the Flavor and Fragrance industry, the company’s main area of focus, ChemCom’s platform and product portfolios represent an innovative approach with successful solutions for:
Thanks to the therapeutic characteristics of GPCRs, ChemCom’s research can also be leveraged in pharmaceutical markets (Drug Discovery: oncology, immunology, etc).
Based on solid results, ChemCom has focused on the proof of concept of its technology.
First code on Olfactory Receptors (ORs) genes (Buck and Axel), showing that they belong to the family of G Protein-Coupled Receptors (GPCRs). They estimated that there were approximately one thousand different genes for ORs in the mammalian genome.
Licensing-in of the chaperones technology from Duke University.
Partnership with Givaudan.
End of partnership with Givaudan.
Partnership with an international group for a research program broken down into several milestones.
Partnership with an international beverage group. Renewal of partnership following encouraging results on first milestone.
First pharmaceutical development. The BioWin project agreement focuses on oncology applications based on GPCRs.